A class of experimental therapeutics that is being tested in both cancer and wound healing indications may have found another home. Researchers from Karyopharm Therapeutics Inc. and collaborators at the Mount Sinai School of Medicine have reported that treatment with a class of drugs they have termed Selective Inhibitors of Nuclear Export, or SINE compounds, slowed down disease progression in mouse models of multiple sclerosis and axonal damage.